RDNT
Get informed when a big investor buys or sells
+ FollowOvervalued by 137.1% based on the discounted cash flow analysis.
| Market cap | $4.23 Billion |
|---|---|
| Enterprise Value | $5.72 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.25 |
| Beta | 1.39 |
| Outstanding Shares | 77,057,835 |
| P/E Ratio | -291.79 |
|---|---|
| PEG | - |
| Price to Sales | 2.15 |
| Price to Book Ratio | 3.42 |
| Enterprise Value to Revenue | 2.67 |
| Enterprise Value to EBIT | 56.42 |
| Enterprise Value to Net Income | -403 |
| Total Debt to Enterprise | 0.34 |
| Debt to Equity | 1.8 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2444▼ 109.05% |
|---|---|
| Total Calls | 137,900▼ 74.78% |
| Total Puts | 33,700▼ 95.38% |
Holdings and activity of institutional investors.
| Ownership % | 102.53%▲ 0.49% |
|---|---|
| Total Invested | $4.31B▼ 20.79% |
| Investors Holding | 347▼ 7.00% |
No data
Controls Medicare and Medicaid policy; legislative movements to expand Medicare to include dental benefits would represent a massive revenue catalyst for the lab industry.
Directly oversees the FDA, which regulates dental materials and the 3D printing technologies increasingly used in dental labs.